Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 8/20 | 0.41 |
| ▸ | CALCR | P30988 | 8/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25524928 | 0.99 | APLNR (0.45) | APLNRNMUR2NMUR1F2RAMP3 | |
| SCHEMBL25524962 | 0.98 | NMUR2 (0.46) | APLNRNMUR2NMUR1F2RAMP3 | |
| SCHEMBL22019477 | 0.96 | NPY2R (0.44) | APLNRNMUR2NMUR1RAMP3CALCR | |
| SCHEMBL25524960 | 0.96 | RAMP3 (0.46) | RAMP3CALCRNPY1RNPY2RNPY4R | |
| SCHEMBL25524949 | 0.96 | F2 (0.45) | F2CALCRNPY1RNPY2RNPY4R | |
| SCHEMBL22018604 | 0.95 | APLNR (0.45) | APLNRRAMP3CALCRNPY1RNPY2R | |
| SCHEMBL25524970 | 0.95 | APLNR (0.44) | APLNRNMUR2NMUR1F2RAMP3 | |
| SCHEMBL22018361 | 0.95 | APLNR (0.46) | APLNRF2RAMP3CALCRNPY1R | |
| SCHEMBL22018477 | 0.95 | APLNR (0.46) | APLNRRAMP3CALCRNPY1RNPY2R | |
| SCHEMBL22922932 | 0.95 | APLNR (0.46) | APLNRRAMP3CALCRNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | VIP, TSLP, IAPP | APLNR 90/4885NMUR2 1237/4885NMUR1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.